Lipocine is a clinical-stage biopharmaceutical company that focuses on addressing metabolic and endocrine disorders. With a commitment to innovation, Lipocine develops proprietary drug delivery technologies that improve drug absorption and enhance patient compliance. Their progressive pipeline includes cutting-edge solutions for neuroendocrine and metabolic disorders.

One of their notable products is TLANDO®, an FDA-approved oral testosterone replacement therapy option that eliminates the need for dose titration. Designed to restore normal testosterone levels in males, TLANDO® offers a convenient and effective treatment option. Lipocine also offers LPCN 1154, an oral neuro-steroid being developed to tackle postpartum depression, and LPCN 1144, an oral prodrug of bioidentical testosterone created for non-alcoholic steatohepatitis (NASH) treatment.

Their groundbreaking Lip'ral technology enables the efficient absorption of water-insoluble drugs, revolutionizing the face of oral absorption drugs. By repositioning established drugs through an efficient regulatory pathway strategy, Lipocine aims to improve patient compliance and overall health outcomes. With a focus on liver disease, low testosterone, recurrent pre-term birth, and postpartum depression, Lipocine is committed to enhancing health and transforming the lives of patients